Introduction
Trans-catheter aortic valve replacement (TAVR) has become a reliable treatment alternative to surgery for aortic stenosis in patients who are inoperable or at a high surgical risk. 1 Recently, the randomized PARTNER II trial showed similar all-cause death and disabling stroke outcomes of both techniques in intermediate-risk patients, thus widening the TAVR indication to lower-risk patients. 2 However, the extension of the indications requires a reduction of several prevalent complications, such as para-valvular regurgitation (PVR), which is associated with a poorer prognosis. 3 Recently, the new expandable Sapien 3 trans-catheter heart valve (S3-THV) has replaced the previous generation of Sapien XT transcatheter heart valve (XT-THV), which was associated with a high prevalence of PVR. S3-THV provides new features, such as an outer annular sealing polyethylene terephthalate skirt that functions as a blood-soaked sponge and limits the risk of PVR. 4 However, by bulging into the annular space, this material could lead to turbulence during ventricular ejection and can potentially increase the transprosthetic gradient (see Supplementary data online, Appendix S1). This could expose patients to an underlying risk of patient-prosthesis mismatch (PPM) that occurs when the effective orifice area (EOA) of a normally functioning prosthetic valve is too small in relation to patient body size. 5 The results from several clinical studies have demonstrated the negative effect of PPM on both functional recovery and life expectancy, emphasizing the need for PPM prevention. 6 Recently, some authors have suggested the preference of TAVR to surgical valves in patients with a high risk of PPM due to improved haemodynamic performance. 7 Even though preliminary prospective studies have shown a dramatic reduction of PVR with S3-THV compared with XT -THV, none of these studies have evaluated the haemodynamic effects of the new skirt on post-operative gradients. 8 In this context, the aim of our study was to retrospectively compare the occurrence of moderate and severe PPM among patients with severe aortic stenosis implanted with S3-THV and XT-THV.
Methods

Study population
This retrospective single-centre study was performed from November 2013-15 at La Timone Hospital, Marseille, France. We included 71 consecutive patients with severe aortic stenosis who underwent TAVR with S3-THV (Edwards Lifesciences LLC, Irvine, CA, USA) and 50 consecutive patients who underwent a SAPIEN XT trans-catheter heart valve implantation (XT-THV) (Edwards Lifesciences LLC, Irvine, CA, USA) after heart team endorsement. International review board approval was obtained. Patients who denied authorization for anonymous publication of their clinical data for research purposes were excluded.
Procedure
Depending on the presence of suitable access sites assessed by the CTscan, TAVR was performed using the transfemoral, transapical, transsubclavian or transaortic approach. The size of the prosthesis was endorsed by the heart team, mainly according to the CT scanned aortic annulus size. 9 General anaesthesia was performed in all patients.
Fluoroscopic guidance guided prosthesis positioning and deployment.
Valve implantation was performed under rapid ventricular pacing. Prosthesis position and function were evaluated with angiography, aortic index measurement, and trans-oesophageal echocardiography. More than moderate aortic regurgitation was treated by post-dilatation or second valve implantation.
Data collection and follow-up assessments
Assessments, including physical examination, NYHA classification, 12 leads electrocardiography and TTE were performed at baseline and at the one-month follow-up. The main exploratory outcome was the occurrence of PPM at 1-month post-TAVR implantation. Secondary exploratory outcomes include the occurrence of PVR, clinical improvement according to NYHA class, in hospital mortality, cardiac tamponade, myocardial infarction, stroke, major bleeding, vascular complication and pacemaker implantation. All outcomes were defined according to the Valve Aortic Research Consortium-2 definitions. 10 The rate of oversizing (%) was calculated using the following formula: %oversizing = [THV nominal area/Multi-slice computed tomography (MSCT) annular -1] Â 100. TTE was performed in a Core laboratory by experienced cardiologists. The EOA was calculated according to the continuity equation. The indexed EOA (iEOA) was calculated as the EOA divided by the Body Surface Area. After TAVR implantation, the iEOA was estimated using the Left Ventricular Outflow Tract (LVOT) diameter and velocity measured immediately proximal to the stent, as previously recommended. 11 Moderate PPM was defined by an iEOA < _ 0.85 cm 2 /m 2 , and severe PPM was defined by an iEAO < 0.65 cm 2 /m 2 . 6 An integrative semi-quantitative approach was used to assess the severity of central and PVR. The left ventricular mass regression ratio was calculated as (1-month follow-up LV mass -Baseline LV mass/Baseline LV mass), similar to functional amelioration (1-month follow-up NYHA-Baseline NYHA/Baseline NYHA).
Statistical analysis
The continuous variables were described by mean, SD, minimum and maximum values. The categorical variables were described by size and percentage. For the baseline analysis, categorical variables were compared with the type of prosthesis using v 2 or Fisher's exact test, according to the conditions of application. The non-parametric Wilcoxon signedrank test was used for continuous variables (paired if comparing baseline to follow-up characteristics).
A large number of preoperative baseline characteristics varied between the two groups. In order to adjust for these between group differences, propensity scores, which estimate the probability of treatment (prosthesis) assignment was calculated with the use of logistic regression. The following baseline and preoperative (unless otherwise stated) covariates were used in a logistic regression model. Regression adjustment for the propensity score was then used (see Supplementary data online, Appendix S2). The comparison of XT-THV to S3-THV was performed in the overall population and in subgroup analysis by prosthesis size, only the 23-and 26-mm groups were included (both the smallest and largest size groups had small sample sizes).
Sensitivity analyses included an alternative method for propensity score modelling, using inverse probability treatment weighting (IPTW). The final propensity score models were evaluated by comparing the covariate distribution and propensity score between groups before and after IPTW. These weights were used in the subsequent logistic regression analysis. The average treatment effect was calculated to answer the question if the valve XT THV results in better outcomes for patients drawn from the population as a whole. The results were considered statistically significant with a P value of P < _ 0.05. Statistical analysis was performed using the software programme R (version 3.1.0).
Results
Baseline and echo characteristics
In total, 121 patients (mean age = 82.4 ± 6.5 years; 60% females) were enrolled: 50 patients to the XT-THV subgroup, and 71 patients to the S3-THV subgroup. Eighty-five patients (70%) had hypertension. The mean BSA was 1.70 , P = 0.04), lower haemoglobin rate (116 ± 17 and 121 ± 17 g/dL, P = 0.04), and lower aortic annulus diameter on TTE (20.2 ± 1.7 mm vs. 21 .5 ± 1.95, P < 0.001) ( Tables 1 and 2 ).
Procedural characteristics
Among the XT-THV patients, three patients had a 20 mm (6%), 24 had a 23 mm (48%), 21 had a 26 mm (42%), and two had a 29 mm (4%). Among the S3-THV patients, 34 had a 23 mm (48%), 30 had a 26 mm (42%), and six had a 29 mm (10%). Aortic annuli were larger with 23mm and 26mm S3-THV, shown by larger MSCT aortic annulus area (P < 0.001) and lower prosthesis to annulus oversizing. Figure  1A and B. There were no differences between the groups regarding procedural events, such as vascular complications or pacemaker implantation. 
Clinical follow-up
Haemodynamic follow-up
The overall echocardiographic data and data according to valve type at 1-month follow-up are provided in Table 3 . The mean gradient decreased significantly from baseline to 1-month follow-up (51.0 ± 16.0 vs. 12.0 ± 5.0 mmHg, P < 0.001), and LVEF slightly increased (60 ± 12 vs. 56 ± 13%, P < 0.001). At 1-month follow-up, the mean EOA was 1 Sixty-one patients (53%) had a PVR at the 1-month follow-up, including 37 patients (82%) in the XT-THV group and 24 patients (34%) in the S3-THV. Among these patients, 47 (77%) had trivial PVR, twelve (20%) had mild/moderate PVR and 2 (3%) had severe PVR. Among the XT-THV group, 26 patients (70%) had trivial PVR, 9 (24%) had mild/moderate PVR and 2 (6%) had severe PVR. Neither moderate nor severe PVR were observed in the S3-THV group, whereas 21 (88%) had trivial PVR and 3 (12%) had mild PVR.
Using a logistic regression adjustment of the propensity score, the odds of a para-prosthetic leak were 98% reduced with S3-THV compared with XT-THV [OR = 0.02, (0.002-0.095), P < 0.001]. 
Discussion
The aim of this study was to compare the occurrence of moderate and severe PPM with the new balloon-expandable S3-THV vs. the preceding XT-THV generation in TAVI for severe AS. The main findings were (i) a higher risk of PPM for S3-THV, (ii) a 15-fold increased risk of PPM with the smallest size of S3-THV prosthesis in comparison with the same size XT-THV prosthesis, and (iii) a similar degree of left ventricular mass regression and NYHA functional improvement with both valves.
The clinical effect of PPM after surgical aortic valve replacement (SAVR) has been a matter of controversy since the first description by Rahimtoola in 1978. 5 PPM occurs if the EOA of the implanted bioprosthesis is small relative to the patient body size. PPM is considered severe when the iEOA is < 0.65 cm The occurrence of PPM post-SAVR is well recognized and ranges from 20 to 70% for moderate PPM and from 2 to 10% for severe PPM. 12 The adverse effects of PPM include functional impairment, reduced LV mass regression and a significant reduction of early and intermediate survival, particularly in severe PPM. 13 A recent meta-analysis of 34 studies with 27 186 patients confirmed a significantly negative effect of PPM on long-term survival, particularly in cases of vulnerability, such as impaired LVEF, severe LV hypertrophy, concomitant mitral regurgitation, and/or paradoxical low flow/low gradient aortic stenosis. 14 When compared with SAVR, the previous prostheses used for TAVR, such as Edwards Sapien and Sapien-XT, tend to have better haemodynamic performance, thus contributing to a reduction in PPM. 15 In a randomized comparison of 699 patients from the PARTNER trial A cohort, TAVR was significantly associated with less PPM (46.4 vs. 60.0%, P < 0.001) and severe PPM (19.7 vs. 28.1%, P < 0.001) compared with SAVR. 7 This study was also the first to identify an important relationship between PPM after TAVR implantation and 2-year mortality, but this relationship was found only in the TAVR nonrandomized continued access arm. The difference in severe PPM was particularly important in patients with small aortic annuli (<20 mm), assuming that the thinner stent frame and absence of a sewing ring in the annular space provide less blood flow obstruction. However, this study was based on the former generation of SAPIEN/ SAPIEN XT-THV, and none of these haemodynamic results could be extended to the new S3-THV generation, which embedded supplementary annular space material. Several studies have compared the two types of XT-THV and S3-THV by focusing on PVR occurrence but, to the best of our knowledge, our study is the first to compare the occurrence of PPM in both prosthesis groups. 4, 16 Our main finding was that S3-THV was associated with a higher risk of moderate and severe PPM than XT-THV implantation. We showed that the iEOA was significantly lower , P = 0.38 and 11.65 ± 5.98 vs. 9 .96 ± 4.77, P = 0.08 for 23 mm prosthesis), but the absence of EOA indexation to BSA did not permit the reporting of the incidence of PPM in this cohort. 4 The increase in both the risk and severity of high trans-prosthetic gradients and PPM could be explained by the outer sealing cuff, which is embedded in the new S3-THV. This new feature bulges into the annular space after deployment to fill up irregularities. In concordance with previous studies, the reduction in rate and severity of PVR was confirmed in our study (34 and 82%, P < 0.001). 17 However, although this novelty achieved a lower rate of PVR, the presence of a supple mentary material occupying the annular space could have favoured a systolic blood obstruction and detrimental haemodynamic performance, particularly in the case of a small aortic annulus. A reduction in aortic annulus oversizing for the S3-THV compared with XT-THV could also explain the increase observed in postoperative gradients. Oversizing was often used with XT-THV to prevent PVR and valve embolization. However, the S3-THV requires less oversizing than the XT-THV because it has a skirt to prevent PVR. In our study, native aortic annuli were smallest for patients implanted with XT-THV than S3-THV. We reported a 38% reduction in annular aortic area oversizing for the S3-THV compared with XT-THV, similar to the results of Nijhoff et al. 16 We could assumed that if similar sizing algorithm has been applied for S3 vs. XT, this would negatively impact the haemodynamics of the S3-THV relative to the XT-THV. In fact, the SAPIEN 3 is a device that shortens substantially when it is deployed. Oversizing may result in under-deployed and 'under-shortened' valve stent, which may in turn lead to suboptimal haemodynamic. Then 16 .55 ± 4.9 mmHg, P = 0.15) but some caution should be taken with regard to the limited size of our study. Similarly, Nijhoff et al. reported that oversizing was not associated with higher trans-prosthetic gradients or reduced EOA in their study. 18 Finally, the rate of balloon post-dilatation was similar in both subgroups and does not explain the haemodynamic difference. The relative LV mass reduction was comparable and incomplete with XT-THV and S3-THV, thus suggesting a persistence of LV afterload in both subgroups. One explanatory hypothesis is that S3-THV had the highest risk of PPM, whereas XT-THV experienced the highest occurrence of PVR. 3 Both haemodynamic sequelae contribute to limiting LV hypertrophy regression, and further investigations are mandatory to evaluate the respective strength of each parameter on myocardial recovery and prognosis. 19 Additionally, baseline aortic regurgitation was significantly more prevalent in the XT-THV group and could have prolonged the duration and limit the completeness of LV mass regression. 20 Finally, the follow-up period was short, and the implanted patients were older and mainly had hypertension. This attribute may have compromised optimal LV remodelling. Taken together, our results suggest that S3-THV reduces the risk of PVR at the expense of having a higher risk of PPM. These findings have to be considered in an era of the extension of the indications to younger patients with less comorbidity, who are more vulnerable to PPM than the elderly.
Strengths and limitations
The main limitations are the retrospective, single-centre, nonrandomized design of the study. However, the use of propensity score analysis is a well-established approach in observational research to address differences between treatments and to reduce bias 
due to confounding variables. 14 We used two transparent methods:
regression adjustment and inverse weighting by the propensity score (IPTW). Two other well-described propensity score approaches were not appropriate (matching and stratification) due to differing population distributions of covariates in the two baseline groups and small sample sizes-including empty propensity score strata and lack of good matches. As there can be disadvantages of regression adjustment, we validated our results using IPTW, which reduces bias and is less vulnerable to extrapolation. This method has been previously used in cardiovascular research and is appropriate for not wellbalanced matches and to retain all study data. 21 The calculation of the 'projected' in vivo indexed EOA is particularly interesting in the clinical decision-making process to avoid the risk of post-operative PPM. The 'projected' in vivo EOA is obtained by dividing the in vivo EOA provided by the manufacturer by the body surface area. 6 For surgical bioprosthesis, manufacturers provide reliable in vivo EOA data for each prosthesis size based on several echocardiographic studies. For a given size, it is assumed that in vivo EOA could not varied from one patient to another because the diameter of a stented bioprosthesis do not varied from one patient to another and the EOA is independent of flow. Concerning THV, many pre-or peri-procedural factors varying from one patient to another, such as the degree of stent deployment, the presence and/or the localization of native valve calcification, the height of valve implantation and the ring anatomy could influence directly the estimation of post-operative iEOA. 11 Consequently, no in vivo iEOA per size are provided by manufacturer for THV. For all these reasons, we didn't use the 'projected' iEAO to diagnose PPM after THV implantation even if the presently reported values for EOA might present a unique frame of reference with regards to the haemodynamic performance to be expected from these prostheses. Several errors can occur in this estimation of iEOA, particularly for TAVR prosthesis where LVOT diameter and LVOT VTI assessment were particularly challenging. In this study, all echocardiography was performed in a core laboratory by two experienced cardiologists to limit the risk of intra/inter-observer variability. . These patients belonged exclusively to the S3-THV group, which could suggest some technical difficulties in SVI calculation in this subgroup. However, the LVOT measurements method was the same for both type of prosthesis and LVOT VTI measurement was also standardized by positioning the pulsed-wave Doppler sample volume at 1.0 cm below the THV insertion. 13 The main reasons to explain the absence of low-flow state with XT-THV were the higher occurrence of PVR and the lower BSA due to a female predominance. Similarly, the higher occurrence of PVR in the XT-THV group could have increased the mean trans-prosthetic gradient. Finally, iEOA may also be underestimated if the ascending aorta diameter is < 30 mm because of the risk of pressure recovery phenomenon. 22 Unfortunately, too many data were missing to provide reliable data concerning the estimation of the energy loss index. 
Conclusion
In this single-centre, retrospective propensity score analysis, we observed an increased risk of PPM only in the smaller size (=23 mm) S3-THV compared with the former generation of XT-THV but not in the larger sizes where the incidence of PPM remains low. In return, the additional sub-annular cuff of the S3-THV prosthesis significantly reduced the occurrence and severity of PVR. Given the enhanced vulnerability of younger patients to the consequences of PPM, these observations should be useful when considering the extension of the TAVR indication to a younger population. 
